A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)
Phase of Trial: Phase I/II
Latest Information Update: 27 Jul 2016
At a glance
- Drugs Apabetalone (Primary)
- Indications Atherosclerosis; Low HDL cholesterol
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Resverlogix Corporation
- 22 Jun 2010 Data presented at the European Atherosclerosis Society Congress, according to a Resverlogix media release.
- 03 Feb 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 29 Sep 2009 Status changed from recruiting to completed, according to a Resverlogix media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History